Equities Analysts Issue Forecasts for AGIO FY2026 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Agios Pharmaceuticals in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the biopharmaceutical company will earn ($6.13) per share for the year. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share.

Several other brokerages have also recently issued reports on AGIO. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective for the company. Finally, Scotiabank decreased their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of "Hold" and an average target price of $56.50.

Agios Pharmaceuticals Trading Up 2.5%

Shares of AGIO stock traded up $0.85 during trading hours on Tuesday, hitting $34.51. The company's stock had a trading volume of 623,874 shares, compared to its average volume of 666,288. The stock has a market cap of $2.00 billion, a PE ratio of 3.04 and a beta of 0.73. Agios Pharmaceuticals has a 12-month low of $23.42 and a 12-month high of $62.58. The company has a 50 day moving average of $29.08 and a 200 day moving average of $34.08.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The company had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at about $33,000. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at $39,000. NewEdge Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals during the first quarter worth $40,000. CWM LLC grew its stake in Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 996 shares in the last quarter. Finally, Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $53,000.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now directly owns 149,220 shares of the company's stock, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.